Apparent mineralocorticoid excess: Time of manifestation and complications despite treatment

Pediatrics

Volumn 127, Issue 6, 2011, Pages

  Knops, Noël B B ^a   Monnens, Leo A ^b   Lenders, Jacques W ^b,c   Levtchenko, Elena N ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Apparent mineralocorticoid excess syndrome; Eplerenone; Mineralocorticoid receptors; Stroke

Indexed keywords

5 BETA TETRAHYDROCORTISOL; 5 BETA TETRAHYDROCORTISONE; ALDOSTERONE; AMILORIDE; ANTICOAGULANT AGENT; ATENOLOL; EPLERENONE; FIBRILLIN 1; FUROSEMIDE; POTASSIUM; RENIN; STEROID; TETRAHYDROCORTISOL; TRIAMTERENE; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; APHASIA; APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTICLE; BLOOD PRESSURE; BRAIN ISCHEMIA; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXON; FAMILY HISTORY; FEMALE; FOOD INTAKE; HEART ATRIUM ENLARGEMENT; HEMIPARESIS; HOMOZYGOSITY; HUMAN; HYPERTENSION; HYPOKALEMIA; INFANT; MARFAN SYNDROME; METABOLIC ACIDOSIS; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SYMPTOMATOLOGY; THROMBOPHILIA; URINARY EXCRETION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; DIET, SODIUM-RESTRICTED; DIETARY SUPPLEMENTS; DNA; FEMALE; FOLLOW-UP STUDIES; HOMOZYGOTE; HUMANS; INFANT; MINERALOCORTICOID EXCESS SYNDROME, APPARENT; MUTATION; PEDIGREE; POTASSIUM; TIME FACTORS;

EID: 79957909024     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-1928     Document Type: Article

References (32)

1. White PC, Mune T, Agarwal AK. 11 β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev. 1997;18(1):135-156 (Pubitemid 27076458)
2. Stewart PM. Mineralocorticoid hypertension. Lancet. 1999;353(9161):1341- 1347 (Pubitemid 29178794)
3. Fiselier TJ, Otten BJ, Monnens LA, Honour JW, van Munster PJ. Low-renin, low-aldosterone hypertension and abnormal cortisol metabolism in a 19-month-old child. Horm Res. 1982;16(2):107-114 (Pubitemid 12123278)
4. Morineau G, Sulmont V, Salomon R, et al. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. J Am Soc Nephrol. 2006;17(11):3176-3184 (Pubitemid 44707778)
5. Nunez BS, Rogerson FM, Mune T, et al. Mutants of 11β-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. Hypertension. 1999;34(4 pt 1):638-642 (Pubitemid 29496446)
6. Honour JW, Dillon MJ, Levin M, Shah V. Fatal, low renin hypertension associated with a disturbance of cortisol metabolism. Arch Dis Child. 1983;58(12):1018-1020 (Pubitemid 14215848)
7. Milford DV, Shackleton CH, Stewart PM. Mineralocorticoid hypertension and congenital deficiency of 11 β-hydroxysteroid dehydrogenase in a family with the syndrome of "apparent" mineralocorticoid excess. Clin Endocrinol (Oxf). 1995;43(2):241-246
8. Fiselier T, Monnens L, van Munster P, Jansen M, Peer P, Lijnen P. The reninangiotensin-aldosterone system in infancy and childhood in basal conditions and after stimulation. Eur J Pediatr. 1984;143(1):18-24 (Pubitemid 14018178)
9. Mehta KP, Karnik SR, Sathe A, Pant R, Khatwani R, Bhise A. Renal parameters during infancy. Indian Pediatr. 1992;29(11):1385-1390
10. Martinerie L, Viengchareun S, Delezoide AL, et al. Low renal mineralocorticoid receptor expression at birth contributes to partial aldosterone resistance in neonates. Endocrinology. 2009;150(9):4414-4424
11. Dötsch J, Hohenberger I, Peter M, Sippell W, Dörr HG. Evidence for change of 11 β-hydroxysteroid dehydrogenase activity during infancy and childhood. Pediatr Res. 2000;48(5):697-700
12. Gurkan S, Estilo GK, Wei Y, Satlin LM. Potassium transport in the maturing kidney. Pediatr Nephrol. 2007;22(7):915-925 (Pubitemid 46881908)
13. Chan YC, Ting CW, Ho P, Poon JT, Cheung GC, Cheng SW. Ten-year epidemiological review of in-hospital patients with Marfan syndrome. Ann Vasc Surg. 2008;22(5):608-612
14. Wityk RJ, Zanferrari C, Oppenheimer S. Neurovascular complications of Marfan syndrome: a retrospective, hospital-based study. Stroke. 2002;33(3):680-684 (Pubitemid 34203989)
15. Mantero F, Palermo M, Petrelli MD, Tedde R, Stewart PM, Shackleton CH. Apparent mineralocorticoid excess: type I and type II. Steroids. 1996;61(4):193-196
16. Dave-Sharma S, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1998;83(7):2244-2254 (Pubitemid 28503009)
17. Brem AS, Bina RB, King TC, Morris DJ. Localization of 2 11β-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension. 1998;31(1 pt 2):459-462
18. Hatakeyama H, Inaba S, Miyamori I. 11β- Hydroxysteroid dehydrogenase in cultured human vascular cells: possible role in the development of hypertension. Hypertension. 1999;33(5):1179-1184 (Pubitemid 29230970)
19. Seckl JR, Dickson KL, Yates C, Fink G. Distribution of glucocorticoid and mineralocorticoid receptor messenger RNA expression in human postmortem hippocampus. Brain Res. 1991;561(2):332-337
20. Watzka M, Beyenburg S, Blümcke I, Elger CE, Bidlingmaier F, Stoffel-Wagner B. Expression of mineralocorticoid and glucocorticoid receptor mRNA in the human hippocampus. Neurosci Lett. 2000;290(2): 121-124 (Pubitemid 30628356)
21. Hadoke PW, Christy C, Kotelevtsev YV, et al. Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11β-hydroxysteroid dehydrogenase. Circulation. 2001;104(23):2832-2837 (Pubitemid 33126659)
22. Dorrance AM, Rupp NC, Nogueira EF. Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension. 2006;47(3):590-595 (Pubitemid 43843881)
23. Osmond JM, Dorrance AM. 11β- Hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia. Endocrinology. 2009;150(2):713-719
24. Dorrance AM, Osborn HL, Grekin R, Webb RC. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol. 2001;281(3):R944-R950
25. Rigsby CS, Pollock DM, Dorrance AM. Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive strokeprone rats. Microvasc Res. 2007;73(3):198-205 (Pubitemid 46601522)
26. Tada Y, Kitazato KT, Tamura T, et al. Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats. Hypertension. 2009;54(3):552-557
27. Jansen PM, Danser AH, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27(4):680-691
28. Li JS, Flynn JT, Portman R, et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr. 2010;157(2):282-287
29. Odermatt A, Dick B, Arnold P, et al. A mutation in the cofactor-binding domain of 11β- hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. J Clin Endocrinol Metab. 2001;86(3):1247-1252 (Pubitemid 32323012)
30. Quinkler M, Bappal B, Draper N, et al. Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Mol Cell Endocrinol. 2004;217(1-2):143-149 (Pubitemid 38596639)
31. Harinck HI, van Brummelen P, Van Seters AP, Moolenaar AJ. Apparent mineralocorticoid excess and deficient 11 β-oxidation of cortisol in a young female. Clin Endocrinol (Oxf). 1984;21(5):505-514 (Pubitemid 15202231)
32. Monder C, Shackleton CH, Bradlow HL, et al. The syndrome of apparent mineralocorticoid excess: its association with 11 β-dehydrogenase and 5 β-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab. 1986;63(3):550-557 (Pubitemid 16050550)